Daniel H. Sterman, M.D., is the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine in the Departments of Medicine and Cardiothoracic Surgery at the New York University Grossman School of Medicine, Director of the Division of Pulmonary, Critical Care, and Sleep Medicine, and Director of the Multidisciplinary Pulmonary Oncology Program at NYU Langone Health in New York City. He was previously lead clinical investigator in the multidisciplinary Thoracic Oncology Research Group at the Perelman School of Medicine at the University of Pennsylvania and the Principal Investigator of the Clinical Trials Project for the Penn NCI thoracic oncology program project grant from 1997-2015.

Dr. Sterman’s research interests are related to the treatment of thoracic malignancies, specifically as they apply to the synergy of molecular medicine, tumor immunotherapy and novel technologies in Interventional Pulmonology. Over the past 25 years, he has focused on the translation of laboratory discoveries from the bench to the bedside: conducting multiple human clinical trials of gene therapy and vaccine therapy for lung cancer, mesothelioma, and other pleural malignancies.

More recently, as Director of the NYU PORT (Pulmonary Oncology Research Team), Dr. Sterman has expanded his research interests into assessment of the immune microenviroment of tumor-draining lymph nodes, as well as the development of local intra-tumoral and intra-nodal immunotherapies. He is currently co-national PI of the LuTK02 clinical trial of intratumoral CAN-2409 in patients with advanced non-small cell lung cancer refractory to immune checkpoint inhibition, as well as global PI of the INFINITE clinical trial, a randomized Phase III clinical trial of intrapleural adenovirus-interferon alpha 2b in combination with chemotherapy as second/third line therapy for unresectable malignant pleural mesothelioma.